Unraveling structural requirements of amino-pyrimidine T790M/L858R double mutant EGFR inhibitors: 2D and 3D QSAR study

被引:3
|
作者
Fatima, Shehnaz [1 ]
Agarwal, Subhash Mohan [1 ]
机构
[1] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, 1-7,Sect 39, Noida 201301, India
关键词
EGFR; double mutant inhibitor; QSAR; TMLR; CELL LUNG-CANCER; DRUG-RESISTANCE; MODEL; MUTATION; DESIGN;
D O I
10.1080/10799893.2018.1494740
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
EGFR is an important drug target in cancer. However, the ineffectiveness of first generation inhibitors due to the occurrence of a secondary mutation (T790M) results in the relapse of the disease. Identification of reversible inhibitors against T790M/L858R double mutants (TMLR) thus is a foremost requirement. In this study, various 2 D and 3 D Quantitative Structure-Activity Relationship models were built for amino-pyrimidine compounds with their known biological activity against TMLR mutants. The model developed using multiple linear regression statistical method via stepwise forward-backward variable selection technique showed the best results in terms of internal and external predictivity. The 2D-QSAR model indicated that the presence of electronegative atom, H-bond donors, moderate slogp, count of number of N atoms separated from O (T_N_O_4), 4pathClusterCount and number of S atom connected with two single bonds (SssSE-index), is required for increasing the inhibitory potential of compounds. Also, the 3D-QSAR model suggested that electronegative group at certain positions along with the presence of bulky groups is beneficial for good inhibition activity of the compounds. Thus, the QSAR models developed in the present work can be used for predicting the TMLR bioactivity of a new series of amino-pyrimidine derivatives. To the best of the author's knowledge, this is the first study which deals with the development of 2 D and 3D-QSAR models for double mutant TMLR inhibitors.
引用
收藏
页码:299 / 306
页数:8
相关论文
共 50 条
  • [31] Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors
    Lei, Hao
    Fan, Shu
    Zhang, Hao
    Liu, Yan-Jie
    Hei, Yuan-Yuan
    Zhang, Jun-Jie
    Zheng, A-Qun
    Xin, Minhang
    Zhang, San-Qi
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 186
  • [32] Novel fluorinated pyrazole-based heterocycles scaffold: cytotoxicity, in silico studies and molecular modelling targeting double mutant EGFR L858R/T790M as antiproliferative and apoptotic agents
    Fayed, Eman A.
    Gohar, Nirvana A.
    Bayoumi, Ashraf H.
    Ammar, Yousry A.
    MEDICINAL CHEMISTRY RESEARCH, 2023, 32 (02) : 369 - 388
  • [33] AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
    Choi, Geunho
    Kim, Daegeun
    Oh, Junehwan
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [34] Isoliquiritigenin Induces Apoptosis and Inhibits Xenograft Tumor Growth of Human Lung Cancer Cells by Targeting Both Wild Type and L858R/T790M Mutant EGFR
    Jung, Sung Keun
    Lee, Mee-Hyun
    Lim, Do Young
    Kim, Jong Eun
    Singh, Puja
    Lee, Sung-Young
    Jeong, Chul-Ho
    Lim, Tae-Gyu
    Chen, Hanyong
    Chi, Young-In
    Kundu, Joydeb Kumar
    Lee, Nam Hyouck
    Lee, Charles C.
    Cho, Yong-Yeon
    Bode, Ann M.
    Lee, Ki Won
    Dong, Zigang
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (52) : 35839 - 35848
  • [35] Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation
    Yan, Qi
    Chen, Yuzhe
    Tang, Baiyou
    Xiao, Qiang
    Qu, Rong
    Tong, Linjiang
    Liu, Jian
    Ding, Jian
    Chen, Yi
    Ding, Ning
    Tan, Wenfu
    Xie, Hua
    Li, Yingxia
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 152 : 298 - 306
  • [36] Discovery of Pteridin-7(8H)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant
    Zhou, Wei
    Liu, Xiaofeng
    Tu, Zhengchao
    Zhang, Lianwen
    Ku, Xin
    Bai, Fang
    Zhao, Zhenjiang
    Xu, Yufang
    Ding, Ke
    Li, Honglin
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (20) : 7821 - 7837
  • [37] Coccinic acid exhibits anti-tumor efficacy against NSCLC harboring EGFR L858R/T790M mutation via the EGFR/STAT3 pathway
    Sun, Peiyuan
    Zhang, Shuanggou
    Qu, Yana
    Li, Xuanyou
    Chen, Guirui
    Wang, Xuanjun
    Sheng, Jun
    Wang, Jing
    BIOORGANIC CHEMISTRY, 2025, 154
  • [38] Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation
    Hao, Yongjia
    Wang, Xia
    Zhang, Tao
    Sun, Deheng
    Tong, Yi
    Xu, Yuqiong
    Chen, Haiyang
    Tong, Linjiang
    Zhu, Lili
    Zhao, Zhenjiang
    Chen, Zhuo
    Ding, Jian
    Xie, Hua
    Xu, Yufang
    Li, Honglin
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (15) : 7111 - 7124
  • [39] Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment
    Wang, Cheng
    Wang, Xin
    Huang, Zhi
    Wang, Tianqi
    Nie, Yongwei
    Yang, Shengyong
    Xiang, Rong
    Fan, Yan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 237
  • [40] Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFRL858R/T790M NSCLCs by the conformation constrained strategy
    Chen, Yang
    Yang, Linlin
    Qiao, Hui
    Cheng, Zhongyu
    Xie, Jiahao
    Zhou, Wenjuan
    Huang, Xin
    Jiang, Yaoxuan
    Yu, Bin
    Zhao, Wen
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 199